Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on March 14, 2017. The filing serves to incorporate a news release regarding a public offering of common shares into the company's Registration Statement on Form F-10 (File No. 333-206994).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the announcement of a capital raise.
Material Changes
The primary material event disclosed is the pricing of a public offering of common shares totaling US$150.5 million.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, operational outlook, specific risks, or contingencies beyond the context of the share offering.
Key Facts for Investor Verification
- The company priced a public offering of common shares for US$150.5 million.
- The offering details are contained in Exhibit 99.1 (News Release) incorporated by reference.
- The filing is associated with an ongoing Registration Statement on Form F-10.
- No operational financial results or comparative period data are included in this specific filing.